News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech (RHHBY) Fighting to Delay Amgen (AMGN)'s Avastin Biosimilar



2/17/2017 6:54:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Roche's (OTCQX:RHHBY) Genentech unit is suing Amgen (AMGN -0.5%) in the U.S. for access to manufacturing information it calls "highly relevant" to determine if Amgen's biosimilar to Avastin (bevacizumab) infringes on its patents. It wants the court to intervene before Amgen's product is approved by the FDA so it has "sufficient time" to assert its patents. The complaint accuses Amgen of obstructing its ability to conduct its analysis.



comments powered by Disqus
Genentech
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES